Nicholas Vogelzang, MD, FASCO, FACP, comments on managing an elderly patient with hormone-sensitive prostate cancer with apalutamide and ADT based on data demonstrated by the phase 3 TITAN trial.
EP. 6: Castrate-Sensitive Prostate Cancer: Monitoring Response to TherapyFebruary 9th 2021
Best practices for monitoring patients’ response to AR-targeted therapy as used to treat castrate-sensitive prostate cancer and considerations for managing patients to help prevent the emergence of castrate-resistant disease.
EP. 7: Castrate-Sensitive Prostate Cancer: TITAN Trial OutcomesFebruary 9th 2021
An overview of the phase 3 TITAN trial in castrate-sensitive prostate cancer and implications for treating appropriate patients with apalutamide and androgen deprivation therapy.
EP. 8: Treatment Advances in Castrate-Sensitive Prostate CancerFebruary 9th 2021
Nicholas Vogelzang, MD, FASCO, FACP, reacts to treatment advances in hormone-sensitive prostate cancer and provides advice to oncologists who work in community settings on best practices for managing these patients using newer treatment strategies.